These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Balmer P; Borrow R Expert Rev Vaccines; 2004 Feb; 3(1):77-87. PubMed ID: 14761245 [TBL] [Abstract][Full Text] [Related]
27. Polysaccharides and membrane vaccines. Poolman JT Adv Biotechnol Processes; 1990; 13():57-86. PubMed ID: 1970737 [No Abstract] [Full Text] [Related]
28. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313 [TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease. Walter EB; Moggio MV; Drucker RP; Wilfert CM Pediatr Infect Dis J; 1990 Sep; 9(9):632-5. PubMed ID: 2235187 [TBL] [Abstract][Full Text] [Related]
31. [Immunity against Neisseria meningitidis in different population groups]. Pauste Ruiz H; García Imia L; Campa Huergo C; Gutiérrez Hernández M; Valcárcel Novo M Rev Cubana Med Trop; 1989; 41(1):135-47. PubMed ID: 2505344 [TBL] [Abstract][Full Text] [Related]
32. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines. Heyderman RS; Davenport V; Williams NA Trends Microbiol; 2006 Mar; 14(3):120-4. PubMed ID: 16469496 [TBL] [Abstract][Full Text] [Related]
33. [Humoral immune response to the capsular polysaccharide of Neisseria meningitidis serogroup C in an antimeningococcal BC vaccination trial in Antioquia, Colombia]. Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Martínez Ruiz O; Nerey MC; Camarasa MA; Bacallao Gallestey J Bol Oficina Sanit Panam; 1995 Apr; 118(4):295-301. PubMed ID: 7779284 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults. Bulkow LR; McMahon BJ; Wainwright RB; Parkinson AJ; Wainwright KY; House J Arctic Med Res; 1993 Jul; 52(3):118-26. PubMed ID: 8397580 [TBL] [Abstract][Full Text] [Related]
35. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
36. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Rosenqvist E; Høiby EA; Wedege E; Caugant DA; Frøholm LO; McGuinness BT; Brooks J; Lambden PR; Heckels JE Microb Pathog; 1993 Sep; 15(3):197-205. PubMed ID: 7505873 [TBL] [Abstract][Full Text] [Related]
37. Production and control of Neisseria meningitidis vaccines. Frasch CE Adv Biotechnol Processes; 1990; 13():123-45. PubMed ID: 2110462 [No Abstract] [Full Text] [Related]
38. The Meningococcal Serogroup B Vaccine Protection Trial in Norway 1988-91. Proceedings of the report meeting. Oslo, September 12-13, 1991. NIPH Ann; 1991 Dec; 14(2):46-251. PubMed ID: 1687482 [No Abstract] [Full Text] [Related]
39. "Herd immunity" and the meningococcal vaccine trial in Norway. Bjune G Lancet; 1992 Aug; 340(8814):315. PubMed ID: 1353236 [No Abstract] [Full Text] [Related]
40. The PROPATRIA trial: best practices at the time were followed. Gooszen HG; Lancet; 2010 Apr; 375(9722):1249-50. PubMed ID: 20362327 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]